Literature DB >> 7651400

Exon and intron sequences, respectively, repress and activate splicing of a fibroblast growth factor receptor 2 alternative exon.

F Del Gatto1, R Breathnach.   

Abstract

Two alternative exons, BEK and K-SAM, code for part of the ligand binding site of fibroblast growth factor receptor 2. Splicing of these exons is mutually exclusive, and the choice between them is made in a tissue-specific manner. We identify here pre-mRNA sequences involved in controlling splicing of the K-SAM exon. The short K-SAM exon sequence 5'-TAGGGCAGGC-3' inhibits splicing of the exon. This inhibition can be overcome by mutating either the exon's 5' or 3' splice site to make it correspond more closely to the relevant consensus sequence. Two separate sequence elements in the intron immediately downstream of the K-SAM exon, one of which is a sequence rich in pyrimidines, are both needed for efficient K-SAM exon splicing. This is no longer the case if either the exon's 5' or 3' splice site is reinforced. Furthermore, if the exon inhibitory sequence is removed, the intron sequences are not required for splicing of the K-SAM exon in a cell line which normally splices this exon. At least three elements are thus involved in controlling splicing of the K-SAM exon: suboptimal 5' and 3' splice sites, an exon inhibitory sequence, and intron activating sequences.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651400      PMCID: PMC230727          DOI: 10.1128/MCB.15.9.4825

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  RNA secondary structure repression of a muscle-specific exon in HeLa cell nuclear extracts.

Authors:  B Clouet d'Orval; Y d'Aubenton Carafa; P Sirand-Pugnet; M Gallego; E Brody; J Marie
Journal:  Science       Date:  1991-06-28       Impact factor: 47.728

2.  Tissue-specific splicing in vivo of the beta-tropomyosin gene: dependence on an RNA secondary structure.

Authors:  D Libri; A Piseri; M Y Fiszman
Journal:  Science       Date:  1991-06-28       Impact factor: 47.728

3.  Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor.

Authors:  P Champion-Arnaud; C Ronsin; E Gilbert; M C Gesnel; E Houssaint; R Breathnach
Journal:  Oncogene       Date:  1991-06       Impact factor: 9.867

4.  Exon definition may facilitate splice site selection in RNAs with multiple exons.

Authors:  B L Robberson; G J Cote; S M Berget
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

5.  Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha.

Authors:  T Uetsuki; A Naito; S Nagata; Y Kaziro
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

6.  The essential pre-mRNA splicing factor SF2 influences 5' splice site selection by activating proximal sites.

Authors:  A R Krainer; G C Conway; D Kozak
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

7.  Regulation of tissue-specific P-element pre-mRNA splicing requires the RNA-binding protein PSI.

Authors:  C W Siebel; R Kanaar; D C Rio
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

8.  A protein factor, ASF, controls cell-specific alternative splicing of SV40 early pre-mRNA in vitro.

Authors:  H Ge; J L Manley
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

9.  Biochemical characterization of U2 snRNP auxiliary factor: an essential pre-mRNA splicing factor with a novel intranuclear distribution.

Authors:  P D Zamore; M R Green
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

10.  Synthetic donor and acceptor splice sites function in an RNA polymerase B (II) transcription unit.

Authors:  G Rautmann; H W Matthes; M J Gait; R Breathnach
Journal:  EMBO J       Date:  1984-09       Impact factor: 11.598

View more
  59 in total

1.  Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.

Authors:  C F Bourgeois; M Popielarz; G Hildwein; J Stevenin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  An exonic splicing silencer in the testes-specific DNA ligase III beta exon.

Authors:  S L Chew; L Baginsky; I C Eperon
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

3.  Requirements for mini-exon inclusion in potato invertase mRNAs provides evidence for exon-scanning interactions in plants.

Authors:  C G Simpson; P E Hedley; J A Watters; G P Clark; C McQuade; G C Machray; J W Brown
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

4.  Interaction of the U1 snRNP with nonconserved intronic sequences affects 5' splice site selection.

Authors:  O Puig; A Gottschalk; P Fabrizio; B Séraphin
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

5.  The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers.

Authors:  Y Cavaloc; C F Bourgeois; L Kister; J Stévenin
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

6.  Modulation of exon skipping by high-affinity hnRNP A1-binding sites and by intron elements that repress splice site utilization.

Authors:  M Blanchette; B Chabot
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

7.  The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

Authors:  T O Tange; C K Damgaard; S Guth; J Valcárcel; J Kjems
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

8.  Control of hnRNP A1 alternative splicing: an intron element represses use of the common 3' splice site.

Authors:  M J Simard; B Chabot
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

9.  Combinatorial control of a neuron-specific exon.

Authors:  E F Modafferi; D L Black
Journal:  RNA       Date:  1999-05       Impact factor: 4.942

Review 10.  Polypyrimidine tract binding protein antagonizes exon definition.

Authors:  E J Wagner; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.